Professor Narayanan Parameswaran's team at the Department of Physiology at Michigan State University announced the results of a study that s...
AstraZeneca plans to hire over 800 employees in Singapore for highly skilled roles ranging from engineering, quality, technical services to global supply c...
Ring Therapeutics, a pioneering life sciences company under Flagship Pioneering dedicated to reshaping gene therapy through its unique commensal virome p...
Bora Pharmaceuticals Co., Ltd. ("Bora" or "the Company", TWSE: 6472), announced that its Board of Directors has approved the acquisition of US-based ...
PacBio , a leading developer of high-quality, highly accurate sequencing solutions, announced the signing of a new Research Collaboration Agre...
LeaderMed Group (LeaderMed), a global pharmaceutical development company, and Combiphar, a leading Indonesian pharmaceutical company in Southeast Asia, ann...
New digital health solution for heart failure management puts patients at the center of their care by providing ability for at-home disease monitoring -...
Altamira Therapeutics announces the extension of its exclusive license with Nuance Pharma to cover Singapore, Malaysia, Thailand, Philippines, Indonesia,...
Singaporean government has introduced a subsidy program to make cell, tissue, and gene therapy products (CTGTP) more accessible to patients. Begi...
Thermo Fisher Scientific, the world leader in serving science, has announced the opening of a new Global Business Services Center (GBSC) in the P...
HUTCHMED announces that it has voluntarily withdrawn its supplemental New Drug Application (“NDA”) in China for fruquintinib in combination w...
Collaboration to improve patient care and epidemiological monitoring in Parkway Group's private hospitals QIAstat-Dx syndromic testing to pr...
Collaboration explores the potential synergistic effects of Checkpoint’s anti-PD-L1, cosibelimab, in combination with the autologous T cell thera...
Senhwa Biosciences, Inc. (TPEx: 6492), announced IND Submission to US FDA for the Phase I/II study of Silmitasertib (CX-4945) in combination with c...
© 2024 Biopharma Boardroom. All Rights Reserved.
